placebo preserved 5.5% additional weight loss at 88 weeks Typical taper window / 8 to 16 weeks of stepwise dose reduction before full stop Switching GLP-1s / direct substitution on the same injection day is generally well tolerated per clinical practice guidelines Long-term therapy indication / AACE guidelines classify obesity as a chronic disease requiring ongoing treatment Cardiovascular benefit / SELECT trial showed 20% MACE reduction with semaglutide 2.4 mg over 34.2 months Why stopping a GLP-1 abruptly almost always triggers weight regain Abrupt discontinuation of a GLP-1 receptor agonist removes a pharmacological brake on appetite, gastric emptying, and reward-pathway signaling all at once
If you experience these symptoms, please contact usimmediately or seek emergency care
Updated July 22, 2026 Retatrutide Side Effects & Safety Data (2026) Trial incidence for retatrutide (reta) side effects GI rates, dysesthesia, and class-level safety concerns
GLP-1 medications lower them
Does this where does this bring Pfizer, you know, within that context
10.1161/CIRCRESAHA.117.310705 48 ReiszJ
